When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Pênfigo

Last reviewed: 13 Feb 2025
Last updated: 13 Aug 2021

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • formação de bolhas erosivas crônica da pele, mucosa ou ambas
  • erosões crônicas da boca (pênfigo vulgar [PV], pênfigo paraneoplásico [PPN])
  • lábios dolorosos (PPN)
  • dispneia (PPN)
Full details

Other diagnostic factors

  • couro cabeludo pruriginoso (PV, PF)
  • epistaxe (PV, PPN)
  • pele dolorosa (PV, PF, PPN)
  • disfagia (PV)
  • pele pruriginosa (PV, PF)
  • conjuntivite (PV, PPN)
Full details

Risk factors

  • idade mais avançada
  • HLA DR4 (pênfigo vulgar [PV])
  • HLA DQ1 (PV)
  • HLA DRB1 (pênfigo paraneoplásico [PPN])
  • neoplasia maligna subjacente (PPN)
  • D-penicilamina
  • inibidores da enzima conversora da angiotensina (ECA)
  • penicilina
  • tiopronina
  • interleucina-2
  • nifedipino
  • rifampicina
  • exposição a insetos hematófagos
Full details

Diagnostic tests

1st tests to order

  • biópsia de pele, coloração de hematoxilina e eosina
  • biópsia de pele, imunofluorescência direta
Full details

Tests to consider

  • imunofluorescência indireta em soro
  • ensaio de imunoadsorção enzimática (ELISA) sérico
  • endoscopia digestiva alta
  • radiografia torácica
  • tomografia do tórax
  • testes de função pulmonar (TFPs)
  • imunoblot sérico (Western Blot)
Full details

Treatment algorithm

ACUTE

pênfigo vulgar leve

pênfigo foliáceo leve

pênfigo vulgar ou pênfigo foliáceo moderado a grave

pênfigo paraneoplásico

ONGOING

pênfigo vulgar ou pênfigo foliáceo moderado a grave 6 meses após a terapia inicial: com controle da doença/remissão completa

pênfigo vulgar ou pênfigo foliáceo moderado a grave 6 meses após a terapia inicial: com remissão completa

pênfigo vulgar ou pênfigo foliáceo moderado a grave 12 a 18 meses após a terapia inicial: remissão completa

pênfigo grave/refratário

Contributors

Authors

Jon H. Meyerle, MD

Associate Professor

Department of Dermatology

Uniformed Services University of the Health Sciences

Bethesda

MD

Disclosures

JHM declares that he has no competing interests.

Grant J. Anhalt, MD

Professor

Department of Dermatology

Johns Hopkins Medical Institution

Baltimore

MD

Disclosures

GJA is a consultant for Janssen on a clinical trial design for an investigational drug for bullous pemphigoid.

Peer reviewers

Daniel Mimouni, MD

Professor

Department of Dermatology

Rabin Medical Center

Petah Tikva

Israel

Disclosures

DM declares that he has no competing interests.

Vesna Petronic-Rosic, MD, MSc

Associate Professor and Clinical Director

Section of Dermatology

University of Chicago

Chicago

IL

Disclosures

VPR declares that she has no competing interests.

Timothy Patton, MD

Assistant Professor of Dermatology

Department of Dermatology

University of Pittsburgh

Pittsburgh

PA

Disclosures

TP declares that he has no competing interests.

  • Pênfigo images
  • Differentials

    • Pênfigo benigno familiar (doença de Hailey-Hailey)
    • Penfigoide bolhoso (PB)
    • Dermatose linear bolhosa por imunoglobulina A (IgA)
    More Differentials
  • Guidelines

    • Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV)
    • Diagnosis and management of pemphigus: recommendations by an international panel of experts
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer